The CLEOPATRA trial demonstrated superior PFS and overall survival when pertuzumab was added to trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer who had not received prior anti-HER2 therapy or chemotherapy for metastatic disease. This evidence concerns the gene ERBB2 and metastatic neoplasm.